Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis.

Date publication

octobre 2018

Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Atreya R, Reinisch W, Peyrin-Biroulet L, Scaldaferri F, Admyre C, Knittel T, Kowalski J, Neurath MF, Hawkey C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30120066

Résumé

The Toll-like-receptor 9 (TLR-9) agonist cobitolimod (DIMS0150, Kappaproct) is a promising therapeutic option for ulcerative colitis (UC) patients.

Mots clés

TLR-9, Therapy, Toll-like receptor-9, Ulcerative colitis

Référence

Dig Liver Dis. 2018 10;50(10):1019-1029